Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects

Main Inclusion Criteria: * Males or females between 18 and 65 years of age * Body mass index for females between 29 and 35 kg/m2 and no more than 37 kgm2 for males * Fasting blood glucose level \< 126 mg/dL at screening * 2 hour postprandial (following 75 grams glucose) blood glucose between 140 to 200 mg/dL * Normal thyroid stimulating hormone with or without thyroid replacement therapy * Fasting triglycerides \< 350 mg/dL * For females of reproductive potential, agree to avoid pregnancy during the study and for 3 months following study completion, have a negative serum and/or urine pregnancy test, and use an acceptable method of birth control * Non-smoker or has not smoked for 6 months prior to the screening visit * No history of alcohol abuse within 2 years * Negative drug screen at screening and baseline * Stable weight (+/- 5%); no history of weight loss or gain (\> 10% body weight) * Must provide voluntary, written, informed consent prior to screening evaluations * Must be able to swallow capsules Main Exclusion Criteria: * Marked prolongation of QT/QTc interval or history of additional risk factors for Torsades de Pointes at screening or baseline * Positive for HIV, HAV, HBV or HCV * History of clinically significant cardiovascular, hepatic, respiratory or renal or endocrine disorders * History of breast and/or prostate cancer * Clinically significant neurological or psychiatric condition, uncontrolled hypertension, clinically significant unstable medical abnormality, chronic disease or active, serious clinical infection or condition * Personal or family member with breast and/or prostate cancer * Malignancy within past 5 years except for successfully treated basal cell carcinoma of the skin * Personal and/or family history of venous thromboembolism * History of stroke and/or heart attack * Medication prohibited from study